Your Oncology CRO Partner
ARG provides flexibility and visibility when managing your oncology clinical trial
We Understand Your Challenges in Oncology:
- Is your project front and center in a busy site?
- Does your CRO have CRAs who understand the therapy and treatment modalities?
- Does the CRO team understand complex protocols?
- Are you getting responsive collaboration from your study partner?
- Is every single patient in each trial valued?
We Can Put the Pieces Together
ARG thrives with both inexperienced and veteran Sponsors because we are driven by ideas and relationships, regardless of project. We understand there is no clear path in many clinical trials, and we have people that ask the right questions. Because our monitors are fully engaged in the process, we have consistently demonstrated the capacity to notice details, share observations, and solve problems.
Our tight, smart, and flexible group combines with the Sponsor’s staff members to make one study team. All of this is possible because, for ARG, every patient in every study is vital.
White Papers From A Technology-Driven CRO
“I really enjoy the science, the new therapies and technologies in oncology. There is always something new to learn. These treatments offer promise for so many children. Working in cancer is not for everyone because it is life and death for these kids. But it is the science and hope that sustains me. I am not alone; we have a like-minded team that works together with our Sponsors.”
ARG Best Practices in Oncology Trials
Focus on Details
- Leverages an ever-expanding network of relationships
- Demonstrates the capacity to be effective when no blueprint exists
- Adapts to unique study circumstances
Engagement with Partners
- Allows us to notice details that drive solutions to trial challenges
- Drives meaningful communication with stakeholders
- Fosters collaboration and innovation with experts in oncology
Transparency For Partners
- Provides lines of sight into budgets for cost and time predictability
- Fosters feedback from stakeholders for constant trial improvement
- Adds value via communication to refine processes and address challenges
Phase I Oncology Trial
Rescued Using TrialVista® CTMS
ARG employs a proprietary, analysis-based surveillance methodology that was developed to identify and minimize potential risks, proactively. DDTM helps improve data quality, ensure trial participant safety, and shorten study cycle times through reduction of amendments to protocol and database updates, ultimately leading to the increased possibility of regulatory approval and reducing the time to market.
Phase I Oncology Expertise
ARG’s expertise in Phase I oncology trials accelerate drug development projects. Our clinical oncology experts have a wide range of experience in adaptive design and cohort management, leverage strong site and KOL relationships, and are bolstered by technology that allows real-time reporting for precise decision-making.
Comprehensive Study Analysis
ARG will provide a landscape that will be strategic in finding the right patients at reliable sites. Within this environment, there will also be examinations and subsequent explanations of competing trials, to ensure the right sites are initiated. ARG will give our sponsors advice and points to consider on protocols from ARG expert oncology clinical scientists.
First in Human (FIH)
ARG is skilled in the support of clinical development plan preparation, protocol design and writing, site selection, and project management in oncology and hematology FIH trials. Our Project Managers have years of early phase experience and are experienced in managing cohorts to reach the correct dosing levels.
Our clinical research monitors are experienced with the major oncology institutions throughout North America and Europe to find the right sites with the right patients. ARG has teams that understand what is needed to work with institutional review boards and biosafety committees, and overall, are experienced from rapid site start-up to on-time database lock.
ARG has therapeutic expertise in oncology and hematology trials and worked in many indications within early phase trials. Phase I oncology trials can be challenging but our CRO expertise, services and technologies are unmatched in the industry.